Phio Pharmaceuticals Corp (PHIO): Price and Financial Metrics
PHIO Price/Volume Stats
| Current price | $0.68 | 52-week high | $6.85 |
| Prev. close | $0.70 | 52-week low | $0.50 |
| Day low | $0.67 | Volume | 35,906 |
| Day high | $0.72 | Avg. volume | 370,387 |
| 50-day MA | $0.80 | Dividend yield | N/A |
| 200-day MA | $1.31 | Market Cap | 3.13M |
PHIO Stock Price Chart Interactive Chart >
Phio Pharmaceuticals Corp (PHIO) Company Bio
Phio Pharmaceuticals Corp operates as a pharmaceutical company. The Company focuses on cancer immunotherapy, as well as offers medicine for other diseases. Phio Pharmaceuticals serves customers in the United Sates.
Latest PHIO News From Around the Web
Below are the latest news stories about PHIO PHARMACEUTICALS CORP that investors may wish to consider to help them evaluate PHIO as an investment opportunity.
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsMARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 2,130,252 shares of common stock of the Company originally issued in October 2018 through June 2023, ha |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers for Wednesday with a breakdown of all the latest news this morning! |
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateMARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended September 30, 2023 and provided a business update. “We have enrolled the first patient in our U.S. clinical trial with PH-762,” announced Phio’s President & CEO, Robert Bitterman. “ |
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin CarcinomasMARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the first patient has been dosed in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells. This clinical trial is d |
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor ControlIntratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoint Inhibition (ICI) therapiesMARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announ |
PHIO Price Returns
| 1-mo | -10.53% |
| 3-mo | 13.33% |
| 6-mo | -47.69% |
| 1-year | -79.70% |
| 3-year | -97.57% |
| 5-year | -99.79% |
| YTD | -10.53% |
| 2023 | -82.97% |
| 2022 | -62.80% |
| 2021 | -62.83% |
| 2020 | -71.40% |
| 2019 | -48.18% |
Continue Researching PHIO
Want to do more research on Phio Pharmaceuticals Corp's stock and its price? Try the links below:Phio Pharmaceuticals Corp (PHIO) Stock Price | Nasdaq
Phio Pharmaceuticals Corp (PHIO) Stock Quote, History and News - Yahoo Finance
Phio Pharmaceuticals Corp (PHIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...